

SAFETY DATA SHEET



Imipenem / Cilastatin / Relebactam Formulation

Version
5.3

Revision Date:
2025/04/14

SDS Number:
67739-00030

Date of last issue: 2023/09/30
Date of first issue: 2015/02/27

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Imipenem / Cilastatin / Relebactam Formulation

Manufacturer or supplier's details

Company : MSD

Address : 126 E. Lincoln Avenue
Rahway, New Jersey U.S.A. 07065

Telephone : +1-908-740-4000

Emergency telephone number : +1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

GHS Classification

Serious eye damage/eye irritation : Category 2A

Respiratory sensitisation : Category 1

Reproductive toxicity : Category 2

Specific target organ toxicity - repeated exposure : Category 2 (Kidney)

Short-term (acute) aquatic hazard : Category 1

Long-term (chronic) aquatic hazard : Category 1

GHS label elements

Hazard pictograms :



SAFETY DATA SHEET



Imipenem / Cilastatin / Relebactam Formulation

Version
5.3

Revision Date:
2025/04/14

SDS Number:
67739-00030

Date of last issue: 2023/09/30
Date of first issue: 2015/02/27

Signal word	:	Danger
Hazard statements	:	<p>H319 Causes serious eye irritation. H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled. H361d Suspected of damaging the unborn child. H373 May cause damage to organs (Kidney) through prolonged or repeated exposure. H410 Very toxic to aquatic life with long lasting effects.</p>
Precautionary statements	:	<p>Prevention: P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P260 Do not breathe dust. P264 Wash skin thoroughly after handling. P273 Avoid release to the environment. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection. P284 Wear respiratory protection.</p> <p>Response: P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing. P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P308 + P313 IF exposed or concerned: Get medical advice/ attention. P337 + P313 If eye irritation persists: Get medical advice/ attention. P342 + P311 If experiencing respiratory symptoms: Call a POISON CENTER/ doctor. P391 Collect spillage.</p> <p>Storage: P405 Store locked up.</p> <p>Disposal: P501 Dispose of contents/ container to an approved waste disposal plant.</p>

Other hazards which do not result in classification

Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture	:	Mixture
Components	:	

SAFETY DATA SHEET



Imipenem / Cilastatin / Relebactam Formulation

Version
5.3

Revision Date:
2025/04/14

SDS Number:
67739-00030

Date of last issue: 2023/09/30
Date of first issue: 2015/02/27

Chemical name	CAS-No.	Concentration (% w/w)
Cilastatin	81129-83-1	>= 30 -< 60
Imipenem	74431-23-5	>= 30 -< 60
Relebactam	1174020-13-3	>= 10 -< 30

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
If not breathing, give artificial respiration.
If breathing is difficult, give oxygen.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reactive airways dysfunction syndrome).
Contact with dust can cause mechanical irritation or drying of the skin.
Causes serious eye irritation.
May cause allergy or asthma symptoms or breathing difficulties if inhaled.
Suspected of damaging the unborn child.
May cause damage to organs through prolonged or repeated exposure.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Imipenem / Cilastatin / Relebactam Formula-tionVersion
5.3Revision Date:
2025/04/14SDS Number:
67739-00030Date of last issue: 2023/09/30
Date of first issue: 2015/02/27

Unsuitable extinguishing media	: None known.
Specific hazards during fire-fighting	: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides Metal oxides
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for firefighters	: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	: Surround spill with absorbents and place a damp covering over the area to minimise entry of the material into the air. Add excess liquid to allow the material to enter into solution. Soak up with inert absorbent material. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.

SAFETY DATA SHEET



Imipenem / Cilastatin / Relebactam Formulation

Version
5.3

Revision Date:
2025/04/14

SDS Number:
67739-00030

Date of last issue: 2023/09/30
Date of first issue: 2015/02/27

Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Technical measures	: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation	: Use only with adequate ventilation.
Advice on safe handling	: Do not breathe dust. Do not swallow. Do not get in eyes. Avoid prolonged or repeated contact with skin. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Keep container tightly closed. Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.
Conditions for safe storage	: Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.
Materials to avoid	: Do not store with the following product types: Strong oxidizing agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Cilastatin	81129-83-1	TWA	5 mg/m3 (OEB 1)	Internal
Imipenem	74431-23-5	TWA	3000 ug/m3 (OEB 1)	Internal
	Further information: RSEN, DSEN			
		Wipe limit	100 µg/100 cm ²	Internal
Relebactam	1174020-13-	TWA	0.3 mg/m3 (OEB	Internal

Imipenem / Cilastatin / Relebactam FormulationVersion
5.3Revision Date:
2025/04/14SDS Number:
67739-00030Date of last issue: 2023/09/30
Date of first issue: 2015/02/27

	3		2)	
--	---	--	----	--

Engineering measures : Use feasible engineering controls to minimize exposure to compound.
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection : Chemical-resistant gloves

Material : Chemical-resistant gloves

Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Colour : White to light yellow

Odour : No data available

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

SAFETY DATA SHEET



Imipenem / Cilastatin / Relebactam Formulation

Version
5.3

Revision Date:
2025/04/14

SDS Number:
67739-00030

Date of last issue: 2023/09/30
Date of first issue: 2015/02/27

Flash point	: Not applicable
Evaporation rate	: Not applicable
Flammability (solid, gas)	: May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	: Not applicable
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapour pressure	: Not applicable
Relative vapour density	: Not applicable
Relative density	: No data available
Density	: No data available
Solubility(ies)	
Water solubility	: soluble
Partition coefficient: n-octanol/water	: Not applicable
Auto-ignition temperature	: No data available
Decomposition temperature	: No data available
Viscosity	
Viscosity, dynamic	: No data available
Viscosity, kinematic	: Not applicable
Explosive properties	: Not explosive
Oxidizing properties	: The substance or mixture is not classified as oxidizing.
Molecular weight	: No data available
Particle characteristics	
Particle size	: No data available

10. STABILITY AND REACTIVITY

SAFETY DATA SHEET



Imipenem / Cilastatin / Relebactam Formulation

Version
5.3

Revision Date:
2025/04/14

SDS Number:
67739-00030

Date of last issue: 2023/09/30
Date of first issue: 2015/02/27

Reactivity	: Not classified as a reactivity hazard.
Chemical stability	: Stable under normal conditions.
Possibility of hazardous reactions	: May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	: Heat, flames and sparks. Avoid dust formation.
Incompatible materials	: Oxidizing agents
Hazardous decomposition products	: No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure	: Inhalation Skin contact Ingestion Eye contact
--	--

Acute toxicity

Not classified based on available information.

Components:

Cilastatin:

Acute oral toxicity	: LD50 (Rat): 8,000 mg/kg LD50 (Mouse): 8,000 mg/kg
---------------------	--

Imipenem:

Acute oral toxicity	: LD50 (Mouse): 10,000 mg/kg
Acute toxicity (other routes of administration)	: LD50 (Rat): > 2,000 mg/kg Application Route: Intravenous LD50 (Mouse): 1,500 mg/kg Application Route: Intravenous

Skin corrosion/irritation

Not classified based on available information.

Components:

Cilastatin:

Species	: Rabbit
Result	: No skin irritation

Relebactam:

Method	: EpiDerm
Result	: No skin irritation

Imipenem / Cilastatin / Relebactam FormulationVersion
5.3Revision Date:
2025/04/14SDS Number:
67739-00030Date of last issue: 2023/09/30
Date of first issue: 2015/02/27**Serious eye damage/eye irritation**

Causes serious eye irritation.

Components:**Cilastatin:**

Species : Rabbit
Result : Moderate eye irritation

Relebactam:

Result : No eye irritation
Method : Bovine cornea (BCOP)

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Components:**Cilastatin:**

Exposure routes : Skin contact
Remarks : No data available

Exposure routes : Inhalation
Remarks : No data available

Imipenem:

Remarks : May cause sensitisation of susceptible persons by inhalation of aerosol or dust.

Exposure routes : Skin contact
Remarks : Not classified due to lack of data.

Relebactam:

Test Type : Local lymph node assay (LLNA)
Exposure routes : Dermal
Result : Not a skin sensitizer.

Germ cell mutagenicity

Not classified based on available information.

Imipenem / Cilastatin / Relebactam FormulationVersion
5.3Revision Date:
2025/04/14SDS Number:
67739-00030Date of last issue: 2023/09/30
Date of first issue: 2015/02/27**Components:****Cilastatin:**

Genotoxicity in vitro : Test Type: Microbial mutagenesis assay (Ames test)
Result: negative

Imipenem:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster lung cells
Result: negative

Test Type: reverse mutation assay
Result: negative

Test Type: unscheduled DNA synthesis assay
Result: negative

Test Type: Chromosomal aberration
Result: negative

Test Type: sister chromatid exchange assay
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test
Species: Mouse
Application Route: Intravenous
Result: negative

Relebactam:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Rat
Application Route: Intraperitoneal injection
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

Suspected of damaging the unborn child.

Imipenem / Cilastatin / Relebactam FormulationVersion
5.3Revision Date:
2025/04/14SDS Number:
67739-00030Date of last issue: 2023/09/30
Date of first issue: 2015/02/27**Components:****Cilastatin:**

Effects on fertility

: Test Type: Fertility/early embryonic development
Application Route: Intravenous
Fertility: LOAEL: 1,000
Symptoms: No adverse effects
Result: No effects on fertility and early embryonic development were detected.

Imipenem:

Effects on fertility

: Test Type: Fertility/early embryonic development
Species: Rat, male and female
Application Route: Intravenous
Fertility: LOAEL: 80 mg/kg body weight
Symptoms: No adverse effects, Reduced foetal weight
Result: No effects on fertility and early embryonic development were detected.

Test Type: Fertility/early embryonic development
Species: Rat, male and female
Application Route: Subcutaneous
Fertility: LOAEL: 320 mg/kg body weight
Symptoms: No adverse effects, Reduced foetal weight
Result: No effects on fertility and early embryonic development were detected.

Effects on foetal development

: Test Type: Development
Species: Monkey
Application Route: Intravenous
Developmental Toxicity: LOAEL: 100 mg/kg body weight
Result: Embryotoxic effects and adverse effects on the offspring were detected., No teratogenic effects

Test Type: Development
Species: Rabbit
Application Route: Intravenous
Developmental Toxicity: NOAEL: 60 mg/kg body weight
Result: No teratogenic effects

Test Type: Development
Species: Rat
Application Route: Intravenous
Developmental Toxicity: NOAEL: 60 mg/kg body weight
Result: No teratogenic effects

Reproductive toxicity - Assessment

: Some evidence of adverse effects on development, based on animal experiments.

Relebactam:

SAFETY DATA SHEET



Imipenem / Cilastatin / Relebactam Formulation

Version
5.3

Revision Date:
2025/04/14

SDS Number:
67739-00030

Date of last issue: 2023/09/30
Date of first issue: 2015/02/27

Effects on fertility

: Test Type: Pre-/postnatal development
Species: Rat
Application Route: Subcutaneous
Fertility: NOAEL: 450 mg/kg body weight

Effects on foetal development

: Test Type: Embryo-foetal development
Species: Rat
Application Route: Intraperitoneal injection
Embryo-foetal toxicity: NOAEL: 450 mg/kg body weight
Result: No effects on foetal development

Test Type: Embryo-foetal development
Species: Mouse
Application Route: Intraperitoneal injection
Embryo-foetal toxicity: NOAEL: 450 mg/kg body weight
Result: No effects on foetal development

Test Type: Development
Species: Rat
Application Route: Intravenous
Developmental Toxicity: NOAEL: >= 450 mg/kg body weight
Result: No effects on fertility and early embryonic development were detected.

Test Type: Development
Species: Rabbit
Application Route: Intravenous
Developmental Toxicity: NOAEL: 450 mg/kg body weight
Result: No effects on foetal development

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs (Kidney) through prolonged or repeated exposure.

Components:

Relebactam:

Target Organs : Kidney
Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Cilastatin:

Species : Rat
NOAEL : >= 500 mg/kg
Application Route : Intravenous

Imipenem / Cilastatin / Relebactam FormulationVersion
5.3Revision Date:
2025/04/14SDS Number:
67739-00030Date of last issue: 2023/09/30
Date of first issue: 2015/02/27

Exposure time	:	90 Days
Remarks	:	No significant adverse effects were reported
Species	:	Monkey
NOAEL	:	>= 500 mg/kg
Application Route	:	Intravenous
Exposure time	:	5 Weeks
Remarks	:	No significant adverse effects were reported

Imipenem:

Species	:	Monkey
NOAEL	:	60 mg/kg
LOAEL	:	150 mg/kg
Application Route	:	Intravenous
Exposure time	:	6 Months
Target Organs	:	Kidney
Species	:	Monkey
NOAEL	:	120 mg/kg
Application Route	:	Subcutaneous
Exposure time	:	6 Months
Remarks	:	No significant adverse effects were reported
Species	:	Rat
NOAEL	:	180 mg/kg
Application Route	:	Intravenous
Exposure time	:	6 Months
Remarks	:	No significant adverse effects were reported
Species	:	Rabbit
LOAEL	:	150 mg/kg
Application Route	:	Intravenous
Target Organs	:	Kidney

Relebactam:

Species	:	Rat, female
NOAEL	:	150 mg/kg
Application Route	:	Intravenous
Exposure time	:	30 d
Species	:	Rat, male
NOAEL	:	450 mg/kg
Application Route	:	Intravenous
Exposure time	:	30 d
Species	:	Monkey
NOAEL	:	25 mg/kg
Application Route	:	Intravenous
Exposure time	:	30 d

SAFETY DATA SHEET



Imipenem / Cilastatin / Relebactam Formulation

Version
5.3

Revision Date:
2025/04/14

SDS Number:
67739-00030

Date of last issue: 2023/09/30
Date of first issue: 2015/02/27

Target Organs : Kidney

Species : Monkey
NOAEL : 37.5 mg/kg
Application Route : Intravenous
Exposure time : 30 d

Species : Monkey
NOAEL : 50 mg/kg
LOAEL : 150 mg/kg
Application Route : Intravenous
Exposure time : 3 Months
Target Organs : Kidney

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Imipenem:

Inhalation : Symptoms: Nausea, Vomiting, Diarrhoea, Fever, hypotension, Dizziness, Drowsiness, Convulsions, pruritis, Rash
Remarks: May cause sensitisation of susceptible persons by inhalation of aerosol or dust.

Relebactam:

Skin contact : Symptoms: Pain, Discomfort, Diarrhoea, Abdominal pain, insomnia, Nausea, sore throat, Vertigo

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Cilastatin:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 111 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 99 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Anabaena flos-aquae): > 99 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

EC50 (Pseudokirchneriella subcapitata (green algae)): > 99

Imipenem / Cilastatin / Relebactam Formula-tionVersion
5.3Revision Date:
2025/04/14SDS Number:
67739-00030Date of last issue: 2023/09/30
Date of first issue: 2015/02/27

mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae): 99 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 99 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity) : EC10 (Pimephales promelas (fathead minnow)): > 9.9 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : EC10 (Daphnia magna (Water flea)): > 10 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Imipenem:

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 78 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Anabaena flos-aquae (cyanobacterium)): 0.0046 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae (cyanobacterium)): 0.002 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

EC50 (Pseudokirchneriella subcapitata (green algae)): > 74 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 74 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

M-Factor (Acute aquatic tox-) : 100

Imipenem / Cilastatin / Relebactam FormulationVersion
5.3Revision Date:
2025/04/14SDS Number:
67739-00030Date of last issue: 2023/09/30
Date of first issue: 2015/02/27

icity)

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 9.4 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 11 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

M-Factor (Chronic aquatic toxicity) : 10

Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Relebactam:

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

EC50 (Americamysis): > 100 mg/l
Exposure time: 96 h

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): 86 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 12 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

EC50 (Anabaena flos-aquae (cyanobacterium)): > 11 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae (cyanobacterium)): 11 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 9.2 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 2.7 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 1,000 mg/l

Imipenem / Cilastatin / Relebactam FormulationVersion
5.3Revision Date:
2025/04/14SDS Number:
67739-00030Date of last issue: 2023/09/30
Date of first issue: 2015/02/27

Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 96.3 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Persistence and degradability**Components:****Cilastatin:**

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 27 %
Exposure time: 28 d
Method: OECD Test Guideline 301B

Imipenem:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 29 %
Exposure time: 28 d
Method: OECD Test Guideline 301B

Relebactam:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 11.3 %
Exposure time: 28 d
Method: OECD Test Guideline 314

Bioaccumulative potential**Components:****Cilastatin:**

Partition coefficient: n-octanol/water : log Pow: -3.53

Imipenem:

Partition coefficient: n-octanol/water : log Pow: < -1

Relebactam:

Partition coefficient: n-octanol/water : log Pow: < -2

SAFETY DATA SHEET



Imipenem / Cilastatin / Relebactam Formulation

Version
5.3

Revision Date:
2025/04/14

SDS Number:
67739-00030

Date of last issue: 2023/09/30
Date of first issue: 2015/02/27

Mobility in soil

Components:

Cilastatin:

Distribution among environmental compartments : log Koc: 2.3

Relebactam:

Distribution among environmental compartments : log Koc: 2.3

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(Imipenem)
Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3077
Proper shipping name : Environmentally hazardous substance, solid, n.o.s.
(Imipenem)
Class : 9
Packing group : III
Labels : Miscellaneous
Packing instruction (cargo aircraft) : 956
Packing instruction (passenger aircraft) : 956
Environmentally hazardous : yes

IMDG-Code

SAFETY DATA SHEET



Imipenem / Cilastatin / Relebactam Formulation

Version
5.3

Revision Date:
2025/04/14

SDS Number:
67739-00030

Date of last issue: 2023/09/30
Date of first issue: 2015/02/27

UN number	:	UN 3077
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Imipenem)
Class	:	9
Packing group	:	III
Labels	:	9
EmS Code	:	F-A, S-F
Marine pollutant	:	yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Minister of Industry Regulation No. 23/M-IND/PER/4/2013 concerning the Revision of Minister of Industry Regulation No. 87/M-IND/PER/9/2009 concerning Globally Harmonized System of Classification and Labelling of Chemicals.

Regulation of the Minister of Health No. 472 of 1996 on the Safeguarding of Substances Hazardous to Health

Hazardous substances that must be registered : Not applicable

Government Regulation No. 74 of 2001 on the Management of Hazardous and Toxic Substances

Hazardous substances approved for use : Not applicable

Prohibited substances : Not applicable

Restricted substances : Not applicable

Regulation of the Ministry of Trade No. 7 of 2022 on Distribution and Control of Hazardous Materials

Type of hazardous materials subject to distribution and control, Annex I : Not applicable

Type of hazardous materials subject to distribution and control, Annex II : Not applicable

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

SAFETY DATA SHEET



Imipenem / Cilastatin / Relebactam Formulation

Version
5.3

Revision Date:
2025/04/14

SDS Number:
67739-00030

Date of last issue: 2023/09/30
Date of first issue: 2015/02/27

IECSC : not determined

16. OTHER INFORMATION

Revision Date : 2025/04/14

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : yyyy/mm/dd

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only

SAFETY DATA SHEET



Imipenem / Cilastatin / Relebactam Formulation

Version
5.3

Revision Date:
2025/04/14

SDS Number:
67739-00030

Date of last issue: 2023/09/30
Date of first issue: 2015/02/27

to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ID / EN